Zamto-cel is an investigational autologous tandem CD20-CD19-directed non-cryopreserved CAR-T cell product for patients (pts) with relapsed/refractory diffuse large b cell lymphoma (r/r DLBCL) in the DALY II USA clinical trial (NCT04792489), a multicenter, open label, single-arm Phase 2 ...
Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.
648. Mitigating Tumor Escape: Tandem Anti-CD20- and CD19 SCFV-Based Chimeric Antigen Receptors (CARs) in Leukemia/LymphomaIn 1954, Bartels and his associates1 reported a patient with plasma cell myeloma (multiple myeloma, myelomatosis) who developed acute renal failure immediately after intravenous...